Jul 2026
Abstract IA05: Eliminating the oncogenic driver: Advancing targeted degradation of KRAS
Oral pan-KRAS degraders are supported as a differentiated therapeutic approach for KRAS-driven cancers, with potential advantages in monotherapy activity, durability, immune engagement, and tolerability relative to pan-RAS targeting.
Kathryn D. Smith
· Clinical Cancer Research · 0 citations